Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

The Development of HKI‐272 and Related Compounds for the Treatment of Cancer

Wissner, Allan, Mansour, Tarek S. · 2008 · Archiv der Pharmazie

Abstract

The development of HKI‐272 and EKB‐569 for the treatment of cancer is described. These compounds function as irreversible inhibitors of some members of the ErbB family of receptor tyrosine kinases. In particular, they target epidermal growth factor receptor (EGFR, also known as ErbB‐1) and human epidermal growth factor receptor‐2 (HER2, also known as ErbB‐2). Both, HKI‐272 and EKB‐569 are 4‐anilino‐3‐cyano quinoline derivatives that contain a 4‐(dimethylamino)crotonamide Michael‐acceptor group at the 6‐position. These compounds inhibit the function of the target enzymes by forming a covalent interaction with a conserved cysteine residue located in the kinase domains of these proteins. The potential advantages of using irreversible inhibitors for this purpose are discussed. We summarize the recent findings concerning some somatic mutations in EGFR and their relevance with respect to the irreversible inhibitors. In particular, we highlight the findings that these irreversible inhibitors retain activity against tumors that have acquired a resistance to the reversible binding inhibitors gefitinib and erlotinib. The promising interim clinical trial results for HKI‐272 and EKB‐569 in treating colon, lung, and breast cancers are summarized.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ardp.200800009

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 174

Metadata

Authors
Wissner, A., & Mansour, T. S.
Venue
Archiv der Pharmazie
Publisher
Wiley
Published
2008-07-11
Volume
341
Issue
8
Pages
465-477
ISSN
  • 0365-6233 (ISSN-L)
  • 1521-4184
OpenAlex
W2053015255
Cited by
174
References
7
FWCI
6.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Development of HKI‐272 and Related Compounds for the Treatment of Cancer. https://app.cochat.ai/papers/10.1002/ardp.200800009
The paper
Wissner, A., & Mansour, T. S. (2008). The Development of HKI‐272 and Related Compounds for the Treatment of Cancer. Archiv der Pharmazie. https://doi.org/10.1002/ardp.200800009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.